Evidence map›Paper›PMID 39596248›Full record

ArticleInternational journal of molecular sciences2024

Evaluation of Biochemical Characteristics and Performance of the 3 Screen ICA ELISA Kit.

Eiji Kawasaki, Yukari Takahashi, Tomoko Komeda, Megumi Sakuma

Abstract readEvaluation Study
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eiji KawasakiDiabetes, Thyroid, and Endocrine Center, Shin-Koga Hospital, Kurume 830-8577, Japan.ORCID 0000-0001-7434-4744
Yukari TakahashiQuality Assurance Section, Cosmic Corporation, Tokyo 112-0002, Japan.
Tomoko KomedaQuality Assurance Section, Cosmic Corporation, Tokyo 112-0002, Japan.
Megumi SakumaQuality Assurance Section, Cosmic Corporation, Tokyo 112-0002, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a fundamental evaluation of the 3 Screen ICA ELISA kit, which can simultaneously measure three major anti-islet autoantibodies important in diagnosing and predicting type 1 diabetes, to assess its usefulness as a measuring reagent. In autoantibody-positive samples, the coefficient of variation for intra-assay variation ranged from 1.37% to 2.50%, inter-assay variation from 2.81% to 3.61%, and lot-to-lot variation from 2.01% to 8.61%, demonstrating good reproducibility. Additionally, interfering substances did not affect the autoantibody titers, and satisfying performance was observed in tests examining the sample freeze-thaw stability. Notably, even when the titer of GAD autoantibodies was below the cut-off value of the GAD autoantibody ELISA, the 3 Screen ICA signal was completely absorbed by recombinant GAD65 protein, indicating that the detection sensitivity for GAD autoantibody in the 3 Screen ICA ELISA is higher than that of the GAD autoantibody ELISA kit. Furthermore, in a study using IASP2020 samples from the Immunology and Diabetes Society, which aims to standardize anti-islet autoantibody assays, this kit achieved excellent results with a sensitivity of 96.0%, specificity of 100%, and accuracy of 98.57%. Measuring multiple anti-islet autoantibodies in combination is crucial for diagnosing and predicting type 1 diabetes. The ELISA kit used in this study is highly versatile and can be used in any measurement facility, making it extremely useful for routine testing.

Indexed as

AutoantibodiesDiabetes Mellitus, Type 1Enzyme-Linked Immunosorbent AssayAdolescentAdultChildChild, PreschoolFemaleGlutamate DecarboxylaseHumansMaleMiddle AgedReagent Kits, DiagnosticReproducibility of ResultsSensitivity and SpecificityYoung AdultAutoantibodiesGlutamate DecarboxylaseReagent Kits, Diagnosticenzyme-linked immunosorbent assayGAD autoantibodyIA-2 autoantibodytype 1 diabetesZnT8 autoantibody

Identifiers

PMID39596248
PMCPMC11595002

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.